|
Valoración DCF de Kiromic BioPharma, Inc. (KRBP)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Kiromic BioPharma, Inc. (KRBP) Bundle
¡Evalúe la perspectiva financiera de Kiromic BioPharma, Inc. (KRBP) como un experto! Esta calculadora DCF (KRBP) proporciona finanzas preladas junto con la flexibilidad para modificar el crecimiento de los ingresos, WACC, los márgenes y otros supuestos esenciales para alinearse con sus predicciones.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -19.0 | -25.7 | -32.5 | -16.3 | -23.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .2 | .5 | 2.1 | 2.8 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -19.2 | -26.2 | -34.6 | -19.1 | -23.8 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 10.2 | 25.4 | .6 | 3.2 | 1.1 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .7 | 2.2 | 7.3 | 2.1 | 2.7 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -1.5 | -1.9 | -4.9 | -.2 | -.4 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -19.2 | -26.3 | -38.0 | -19.4 | -23.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -19.8 | -26.2 | -35.7 | -22.0 | -23.6 | -2.7 | .0 | .0 | .0 | .0 |
| WACC, % | 10.36 | 10.36 | 10.36 | 10.36 | 10.36 | 10.36 | 10.36 | 10.36 | 10.36 | 10.36 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | 13 | |||||||||
| Equity Value | -16 | |||||||||
| Diluted Shares Outstanding, MM | 26 | |||||||||
| Equity Value Per Share | -0.61 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real KRBP financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effects of your inputs on Kiromic BioPharma's valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Data: Kiromic BioPharma's (KRBP) historical financial reports and projected forecasts included.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and EBITDA margins to fit your analysis.
- Real-Time Calculations: Instantly view the intrinsic value of Kiromic BioPharma (KRBP) as it updates live.
- Intuitive Visualizations: Dashboard graphs present valuation outcomes and essential metrics clearly.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-built Excel file containing Kiromic BioPharma's (KRBP) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and analyze outcomes instantly.
- Make Decisions: Leverage the valuation results to inform your investment strategy.
Why Choose Kiromic BioPharma's Calculator?
- Precision: Utilizes real Kiromic BioPharma financials for reliable data accuracy.
- Adaptability: Built to allow users to easily test and adjust inputs as needed.
- Efficiency: Eliminate the complexity of constructing a DCF model from the ground up.
- Expert-Level: Crafted with the precision and usability expected by CFOs.
- Intuitive: Designed for ease of use, even for those without extensive financial modeling skills.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for assessing investment opportunities in Kiromic BioPharma, Inc. (KRBP).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Offer clients precise valuation insights for Kiromic BioPharma, Inc. (KRBP) stock.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech companies like Kiromic BioPharma, Inc. (KRBP) are valued in the marketplace.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Kiromic BioPharma historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Kiromic BioPharma, Inc. (KRBP).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.